Literature DB >> 26446610

The Influence of Influenza and Pneumococcal Vaccines on Community-Acquired Pneumonia (CAP) Outcomes Among Elderly Patients.

Paul O Gubbins1, Chenghui Li2.   

Abstract

Elderly are at high risk for hospitalization for community-acquired pneumonia (CAP), especially due to Streptococcus pneumoniae, and seasonal influenza viruses. Data suggest PPV23's influence on various CAP-related outcomes among the elderly may depend upon how many years have elapsed since they received this vaccine. PPV23's protection against invasive pneumococcal disease and CAP hospitalizations are often limited to moderately ill elderly, who are less than 75 years old, or female. PCV13 demonstrates broad protection against a variety of CAPs, but ultimately, its influence on their outcomes among the elderly may be limited by herd immunity from PCV7 use. Influenza vaccine's indirect protective effect against all-cause and non-invasive pneumococcal CAP in the elderly is difficult to ascertain. The use of both PPV23 and influenza vaccine shortens length of stay in hospitalized elderly with CAP, but whether that benefit would be realized in the presence of herd immunity is unknown.

Entities:  

Keywords:  13-valent pneumococcal conjugate vaccine; 23-valent pneumococcal polysaccharide vaccine; Community-acquired pneumonia outcomes; Elderly; Seasonal influenza vaccine

Year:  2015        PMID: 26446610     DOI: 10.1007/s11908-015-0505-6

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  29 in total

Review 1.  The co-pathogenesis of influenza viruses with bacteria in the lung.

Authors:  Jonathan A McCullers
Journal:  Nat Rev Microbiol       Date:  2014-03-03       Impact factor: 60.633

2.  The effectiveness of the polysaccharide pneumococcal vaccine for the prevention of hospitalizations due to Streptococcus pneumoniae community-acquired pneumonia in the elderly differs between the sexes: results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study.

Authors:  Timothy L Wiemken; Ruth M Carrico; Sabra L Klein; Colleen B Jonsson; Paula Peyrani; Robert R Kelley; Stefano Aliberti; Francesco Blasi; Ricardo Fernandez-Gonzalez; Gustavo Lopardo; Julio A Ramirez
Journal:  Vaccine       Date:  2014-03-06       Impact factor: 3.641

Review 3.  The role of influenza in the severity and transmission of respiratory bacterial disease.

Authors:  Michael J Mina; Keith P Klugman
Journal:  Lancet Respir Med       Date:  2014-08-15       Impact factor: 30.700

4.  Prospective cohort study on the effectiveness of influenza and pneumococcal vaccines in preventing pneumonia development and hospitalization.

Authors:  Joon Young Song; Jin Soo Lee; Seong-Heon Wie; Hyo Youl Kim; Jacob Lee; Yu Bin Seo; Hye Won Jeong; Shin Woo Kim; Sun Hee Lee; Kyung-Hwa Park; Ji Yun Noh; Won Suk Choi; Hee Jin Cheong; Woo Joo Kim
Journal:  Clin Vaccine Immunol       Date:  2014-12-24

5.  Evolution of pneumococcal infections in adult patients during a four-year period after vaccination of a pediatric population with 13-valent pneumococcal conjugate vaccine.

Authors:  Antoni Payeras; Aroa Villoslada; Margarita Garau; Ma Neus Salvador; Ma Carmen Gallegos
Journal:  Int J Infect Dis       Date:  2014-12-23       Impact factor: 3.623

6.  Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.

Authors:  Matthew R Moore; Ruth Link-Gelles; William Schaffner; Ruth Lynfield; Catherine Lexau; Nancy M Bennett; Susan Petit; Shelley M Zansky; Lee H Harrison; Arthur Reingold; Lisa Miller; Karen Scherzinger; Ann Thomas; Monica M Farley; Elizabeth R Zell; Thomas H Taylor; Tracy Pondo; Loren Rodgers; Lesley McGee; Bernard Beall; James H Jorgensen; Cynthia G Whitney
Journal:  Lancet Infect Dis       Date:  2015-02-03       Impact factor: 25.071

7.  A worldwide perspective of nursing home-acquired pneumonia compared with community-acquired pneumonia.

Authors:  Adamantia Liapikou; Eva Polverino; Catia Cilloniz; Paulo Peyrani; Julio Ramirez; Rosario Menendez; Antoni Torres
Journal:  Respir Care       Date:  2013-11-05       Impact factor: 2.258

8.  Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis.

Authors:  Carlos G Grijalva; J Pekka Nuorti; Patrick G Arbogast; Stacey W Martin; Kathryn M Edwards; Marie R Griffin
Journal:  Lancet       Date:  2007-04-07       Impact factor: 79.321

Review 9.  After adjusting for bias in meta-analysis seasonal influenza vaccine remains effective in community-dwelling elderly.

Authors:  Maryam Darvishian; Giedre Gefenaite; Rebecca M Turner; Petros Pechlivanoglou; Wim Van der Hoek; Edwin R Van den Heuvel; Eelko Hak
Journal:  J Clin Epidemiol       Date:  2014-04-24       Impact factor: 6.437

10.  Rates of pneumococcal disease in adults with chronic medical conditions.

Authors:  Kimberly M Shea; John Edelsberg; Derek Weycker; Raymond A Farkouh; David R Strutton; Stephen I Pelton
Journal:  Open Forum Infect Dis       Date:  2014-05-27       Impact factor: 3.835

View more
  2 in total

Review 1.  Impact of pneumococcal conjugate vaccines on hospitalizations for pneumonia in the United States.

Authors:  Andrew D Wiese; Marie R Griffin; Carlos G Grijalva
Journal:  Expert Rev Vaccines       Date:  2019-03-20       Impact factor: 5.217

2.  A Perfect Storm: Increased Colonization and Failure of Vaccination Leads to Severe Secondary Bacterial Infection in Influenza Virus-Infected Obese Mice.

Authors:  Erik A Karlsson; Victoria A Meliopoulos; Nicholas C van de Velde; Lee-Ann van de Velde; Beth Mann; Geli Gao; Jason Rosch; Elaine Tuomanen; Jon McCullers; Peter Vogel; Stacey Schultz-Cherry
Journal:  mBio       Date:  2017-09-19       Impact factor: 7.867

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.